News
2d
TipRanks on MSNBioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer
The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is compared against standard chemotherapy options, doxorubicin or paclitaxel, chosen ...
On August 23, 2021 the Food and Drug Administration fully approved the Phizer-BioNTech COVID-19 Vaccine for adults.
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...
BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...
Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that ...
Germany's BioNTech , Pfizer's partner on COVID-19 vaccines, cut its drug development budget for this year after quarterly revenues were hurt by a plunge in pandemic-related demand.
Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...
Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results